Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 2/20 | 0.53 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 13/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16653844 | 1.00 | PRKDC (0.53) | PRKDCSLC40A1FAAHKDM4EALDH1A1 | |
| SCHEMBL29392854 | 1.00 | PRKDC (0.53) | PRKDCSLC40A1FAAHKDM4EALDH1A1 | |
| SCHEMBL17874734 | 0.96 | PRKDC (0.57) | PRKDCSLC40A1FAAHKDM4EALDH1A1 | |
| SCHEMBL17874684 | 0.95 | PRKDC (0.52) | PRKDCSLC40A1FAAHKDM4EALDH1A1 | |
| SCHEMBL16654055 | 0.92 | PRKDC (0.63) | PRKDCSLC40A1FAAHKDM4EALDH1A1 | |
| SCHEMBL28551259 | 0.92 | PRKDC (0.63) | PRKDCSLC40A1FAAHKDM4EALDH1A1 | |
| SCHEMBL29623963 | 0.92 | PRKDC (0.63) | PRKDCSLC40A1FAAHKDM4EALDH1A1 | |
| SCHEMBL15328700 | 0.92 | PRKDC (0.63) | PRKDCSLC40A1FAAHKDM4EALDH1A1 | |
| SCHEMBL17874765 | 0.92 | PRKDC (0.55) | PRKDCFAAHKDM4EALDH1A1CYP1A2 | |
| SCHEMBL17874686 | 0.91 | PRKDC (0.54) | PRKDCSLC40A1FAAHKDM4EAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10716789-B2 | Co-crystals and pharmaceutical compositions comprising the same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-07-21 | — | — | US | claimed |
| EP-3424920-B1 | CO-CRYSTALS OF (S)-N-METHYL-8-(1-((2'-METHYL-[4,5'-BIPYRIMIDIN]-6-YL)AMINO)PROPAN-2-YL)QUINOLINE-4-CARBOXAMIDE AND DEUTERATED DERIVATIVES THEREOF AS DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2020-04-15 | — | — | EP | claimed |
| EP-3424920-A1 | CO-CRYSTALS OF (S)-N-METHYL-8-(1-((2'-METHYL-[4,5'-BIPYRIMIDIN]-6-YL)AMINO)PROPAN-2-YL)QUINOLINE-4-CARBOXAMIDE AND DEUTERATED DERIVATIVES THEREOF AS DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2019-01-09 | — | — | EP | claimed |
| US-20180325897-A1 | CO-CRYSTALS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2018-11-15 | — | — | US | claimed |
| US-10039761-B2 | Co-crystals and pharmaceutical compositions comprising the same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-08-07 | — | — | US | claimed |
| US-20160339024-A1 | CO-CRYSTALS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-11-24 | — | — | US | claimed |
| US-20240374764-A1 | COMBINATION RADIOTHERAPY | TELIX PHARMACEUTICALS (INNOVATIONS) PTY LTD. (AU) | 2024-11-14 | — | — | US | disclosed |
| EP-4387667-A1 | COMBINATION RADIOTHERAPY | Telix Pharmaceuticals (Innovations) Pty Ltd (AU) | 2024-06-26 | — | — | EP | disclosed |
| WO-2023019308-A1 | COMBINATION RADIOTHERAPY | Telix International Pty Ltd (AU) | 2023-02-23 | — | — | WO | disclosed |
| US-11021465-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-06-01 | — | — | US | disclosed |
| US-11008305-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3459942-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2020-12-30 | — | — | EP | disclosed |
| US-10716789-B2 | Co-crystals and pharmaceutical compositions comprising the same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-07-21 | — | — | US | disclosed |
| US-9296701-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150111871-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150111871-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-04-23 | — | — | US | disclosed |
| US-20140045869-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-02-13 | — | — | US | disclosed |
| US-20140045869-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-02-13 | — | — | US | disclosed |
| US-20130281431-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
| US-20130281431-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045869-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | PRKDC 33/4885SLC40A1 4477/4885FAAH 3955/4885 |
| US-20160339024-A1 | CO-CRYSTALS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | SUCNR1, SDHA, SDHB | PRKDC 4779/4885SLC40A1 599/4885FAAH 408/4885 |
| US-11008305-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | PRKDC 33/4885SLC40A1 4477/4885FAAH 3955/4885 |
| US-20150111871-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | PRKDC 33/4885SLC40A1 4477/4885FAAH 3955/4885 |
| US-10716789-B2 | Co-crystals and pharmaceutical compositions comprising the same | SUCNR1, SDHA, SDHB | PRKDC 4779/4885SLC40A1 599/4885FAAH 408/4885 |
| US-10039761-B2 | Co-crystals and pharmaceutical compositions comprising the same | SUCNR1, SDHA, SDHB | PRKDC 4779/4885SLC40A1 599/4885FAAH 408/4885 |
| US-20130281431-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | PRKDC 33/4885SLC40A1 4477/4885FAAH 3955/4885 |
| US-11021465-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | PRKDC 33/4885SLC40A1 4477/4885FAAH 3955/4885 |
| US-20180325897-A1 | CO-CRYSTALS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | SUCNR1, SDHA, SDHB | PRKDC 4779/4885SLC40A1 599/4885FAAH 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.